Skip to content
Open access

LC-MS/MS Quantification and Solvent-Exposure Modeling Reveal a Mismatch Between Linker Exposure and Payload Release in Wild-Type Trastuzumab-VC-PABC-MMAE in Rat Plasma.

Jul 2026 · Biomedical chromotography · Vol 40 9, pp. e70558 · 0 citations · 9 references
Medicine

TL;DR

A mismatch between modeled exposure and observed release argues against a simple exposure-driven cleavage mechanism as the primary explanation for the wild-type behavior and suggests that the observed payload release is influenced by bond chemistry in addition to linker exposure.

Abstract

Free monomethyl auristatin E (MMAE) released from trastuzumab-valine-citrulline-p-aminobenzyl carbamate (VC-PABC)-MMAE conjugates was quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) after incubation in rat plasma at 37°C for 4 days. A wild-type conjugate prepared by maleimide-thiol interchain cysteine conjugation showed 4% ± 3.5% release (n = 3 for each), whereas a Lys188-selective comparator prepared by click chemistry after lipoic acid ligase A-mediated modification showed 4% ± 3.5% release. To examine whether this difference could be explained by linker-payload exposure, molecular dynamics simulations were performed, and solvent-accessible surface areas (SASA) were calculated for representative wild-type interchain cysteine environments and for the Lys188 conjugate. Mean SASA values for the wild-type models were 1132-1293 Å2, all lower than that of the Lys188 model (1524 Å2). Thus, the more stable comparator exhibited the highest modeled exposure. This mismatch between modeled exposure and observed release argues against a simple exposure-driven cleavage mechanism as the primary explanation for the wild-type behavior. Instead, the results suggest that the observed payload release is influenced by bond chemistry in addition to linker exposure.

Read PDF

Similar papers

Open access Sep 2026

Backbone-matched comparison of two trastuzumab-based antibody–drug conjugates: payload localization and gas-phase heterogeneity of trastuzumab deruxtecan and trastuzumab rezetecan

Antibody–drug conjugates (ADCs) are biotherapeutics that are structurally heterogeneous due to the way each ADC is formed. Therefore, complementary analytical approaches need to be used in order to achieve a complete characterization of all aspects of the structure of these biotherapeutics. This project created a multi...

HeeJae Yoo, Abhik Mojumdar, Minsun Kim et al. · 0 citations
#protein folding Aug 2026

Development and ICH M10-compliant validation of an LC-MS/MS method for quantification of atirmociclib in mouse plasma and its application to preclinical pharmacokinetic studies.

The first validated liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method for the quantification of atirmociclib in mouse plasma is reported, validated in compliance with international council for harmonisation-M10 (ICH-M10) guidelines.

Ashwani Gaur, U. Patel, Ashutosh Gavali et al. · 0 citations
Aug 2026

A DAR sensitive hybrid LBA-LC-MS/MS assay for quantitation of conjugated payload from a non-cleavable ADC in human serum.

BACKGROUND Quantitating antibody drug conjugates (ADCs) with traditional ligand binding assays (LBAs) requires cytotoxic payload targeting reagents, which may be needed for ADC capture/detection. LBAs are drug antibody ratio insensitive (DAR insensitive) and prone to under- or over-estimating DAR species. METHODS Thi...

Yong-Jun Xue, Eric Ma, Brian Melo et al. · 0 citations
Open access Sep 2026

Development and validation of an LC-MS/MS method for the novel PROTAC KT-474 in rat and mouse plasma: Application to dose-dependent pharmacokinetics and metabolite identification in mice.

A sensitive liquid chromatography-tandem mass spectrometry method is developed and validated for the quantification of KT-474 in rat and mouse plasma and successfully applied it to pharmacokinetic studies in mice, providing a comprehensive characterization of the pharmacokinetic and metabolic properties of KT-474.

Ji-Hoon Oh, Dang-Khoa Vo, H. Maeng · 0 citations
Open access Sep 2026

LC–MS/MS Method Development and Validation for Quantification of Repotrectinib in Rat Plasma and its Application to Pharmacokinetic Study

The developed LC-MS/MS method for quantifying repotrectinib in rat plasma exhibited reliability and suitability for pharmacokinetic evaluation, as evidenced by a Cmax of 52.30±0.79 ng/ml at Tmax of 5 h in rats.

Sathish Sabbani, G. Chakravarthi, N. Malothu · 0 citations
Open access Sep 2026

Development and Validation of a UPLC–MS/MS Method for Simultaneous Quantification of Ensartinib and Its Major Metabolite M465 in Rat Plasma and Application to Pharmacokinetic Studies

A sensitive, reliable, and rapid UPLC–MS/MS method was developed and validated for the simultaneous determination of ensartinib and M465 in rat plasma and applied to a rat pharmacokinetic study and provides useful analytical support for further preclinical investigations of ensartinib and its major metabolite.

Shi-Qi Jiang, Yan Chen, Lu Cao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.